Infectious Diseases Scientist, HIV/HBV/EBV Research

IMMUNOCORE LTD; Newnham Murren; On-site; GBP 35,000 - 52,000; Full time

Job summary

Immunocore Ltd is seeking a Scientist - Infectious Diseases based in Oxford to contribute to the ImmTAX platform and other modalities for novel infections including HIV, HBV and EBV-related diseases. You will plan, design, and execute experiments, analyze data, and present outcomes at internal meetings.

The role involves engaging with cross-functional teams to push the project forward, with opportunities to expand knowledge in HIV/HBV/EBV biology and drug development within a collaborative

Qualifications

• PhD or equivalent with 0–2 years related experience; alternatively BSc/MSc with substantial bench experience.
• Experience with molecular and cellular techniques used in infectious disease research.
• Willingness to work in a CL3 facility and handle human viruses.

Responsibilities

• Plan, design and execute experiments to meet project goals within defined timeframes.
• Conduct experiments addressing key scientific questions across molecular/cellular assays.
• Analyse data, interpret results, and make recommendations.
• Present results at internal meetings and share findings at external meetings as appropriate.
• Collaborate across cross-functional teams to advance the pipeline and technology capabilities.

Skills

NextGen sequencing

DD-PCR

qPCR

cell culture

flow cytometry

ELISpots

ELISAs

Education

PhD in molecular biology, cell biology, genomics, virology, immunology, or related discipline

BSc or MSc with significant relevant experience

Tools

CL3 containment experience

Job description

Immunocore Ltd is seeking a Scientist - Infectious Diseases based in Oxford to contribute to the ImmTAX platform and other modalities for novel infections including HIV, HBV and EBV-related diseases. You will plan, design, and execute experiments, analyze data, and present outcomes at internal meetings.

The role involves engaging with cross-functional teams to push the project forward, with opportunities to expand knowledge in HIV/HBV/EBV biology and drug development within a collaborative